* INTEGRAGEN *
2000 - IDF
Évry
(near Paris)
www.integragen.com Discovery, Diagnostics
Key words: Genes, Genomic mutations, Diabetes, Obesity, Bipolar disorders, Schizophrenia, Autism, GenomeHIP
Mission: to research in gene targets and to market molecular diagnostics products and services that provide clinicians with new tools of personalized diagnosis, treatment, and therapy
Clients: Prescribers
business@integragen.com
Age: 10 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Spin-off |
Managing Dir.-CEO: Courtieu (Bernard) [born 1964, Vet.D., MBA, ex-Gemini Conseil, Ariba]
Sc.Dir.-CSO: Hager (Jörg) [co-founder, Ph.D., ex-Pasteur Lille]
I.T.Dir.-CIO: Gesnouin (Philippe) [co-founder, ex-Xeotron, Lexicon Genetics]
Fin.Dir.-CFO: Court (Patrick) [born 1958, Sup de Co (Paris), ISG]
SalesMktg: Martin (Emmanuel) [Pharm.D., ex-Applied Biosystems]
BusDev: Brady (David) [MBA, ex-Biogen-Idec, Lonza]
Financers (Hist.): CDC Innovation, GenAvent, Bioam, Bay Tech, AGF P.E., Société Générale A.M., DSM | Turnover (M€) : 2.26 (2008), 0.53 (2006)
Total funding (M€) : 16.3
Last funding (M€) : 2.0
Focus : Cardiovasc
Position : Clinical
Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2010 .04 | Research : positive results on combined analysis of several options in a genetic score to identify individuals with high risks of developing autisme | R&D | [9 years] |
| 2010 .02 | Licensing-out to Transgenomic to develop and distribute its genetic test of autisme in USA | LICOUT | [9 years] |
| 2010 .01 | Licensing-in of technology to set-up a service lab in genetic analysis and a demo lab in Europe, from Fluidigm (USA) | LICIN | [9 years] |
| 2009 .06 | Partnering research agreement with Servier for genotyping applications in Servier's Genese clinical trial | R&D | [8 years] |
| 2007 .09 | Nomination : Bernard Courtieu as CEO, replacing Jan Mous | ORGN | [7 years] |
| 2006 .12 | Set-up of US subsidiary (operations) in New York State | ORGC | [6 years] |
| 2006 .11 | 3rd round-financing : 2.0 M€, by Royal DSM, within a research agreement to develop molecular diagnostics | RFINC | [6 years] |
| 2005 .11 | 2nd round-financing : 8.0 M€, by AGF P.E., Société Générale A.M., and previous shareholders | RFINB | [5 years] |
| 2004 .01 | Research : discovery of a human gene linked to autism | R&D | [3 years] |
| 2003 .07 | Nomination : Jan Mous as CEO [born 1950, Ph.D., ex-Lion Bioscience AG, as CSO, Roche], replacing Jean-Luc Gerbier | ORGN | [3 years] |
| 2001 .06 | 1st round-financing : 6.3 M€, by CDC Innovation, GenAvent, Bioam, Bay Tech | RFINA | [0 year] |
| 2000 .03 | Company founded by Philippe Gesnouin (CIO), Jörg Hager, Anne Philippi, Nathalie Vionnet, Jean-Luc Gerbier [CEO, ex-BMS, Biostar], Peter Brooks, as a spin-off from CNG (Centre National du Génotypage) | ORGF | [0 year] | Actualisation / Updating: 20-Mai-2010 |
|
